

17W

United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US	
Form PTO/SB/21 (Modified)		<b>General Transmittal Form</b>	
Application No.	10/698,894	Attorney Docket	ARC3244R1
Filed (yyyy-mm-dd)	2003-10-31	Customer No.	27777
Applicant	Liang C. Dong	Confirmation No.	2950
Examiner		Art Unit	1615
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Preliminary <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52/1.53 <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition to Revive Abandoned Application <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Petition <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Associate <input type="checkbox"/> Revocation & New <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund		<input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group ( <i>Appeal Notice, Brief, Reply Brief</i> ) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Acknowledgement Postcard	
		<input type="checkbox"/> Other Enclosure(s) (please identify below):	
		Remarks:	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm/Individual	Adenike A. Adewuya, Reg. 42,254		
Signature	<i>Adenike Adewuya</i>		
Date	July 9, 2004		
CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Adenike A. Adewuya		
Signature	<i>Adenike Adewuya</i>	Date	July 9, 2004

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US	
<b>Information Disclosure Statement</b>			
Application No.	10/698,894	Attorney Docket	ARC3244R1
Filed (yyyy-mm-dd)	2003-10-31	Customer No.	27777
Applicant	Liang C. Dong	Confirmation No.	2950
Examiner		Art Unit	1615
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

Applicant submits<sup>1</sup>:

☒ References listed on the attached form PTO 1449\*.

☒ Copies of references are enclosed (U.S. patents/applications omitted if filing date is after June 30, 2003).

☐ A copy of a communication from a foreign patent office in a counterpart application is enclosed.

☐ English language version of foreign search report indicating degree of relevance is enclosed.

☐ Under 35 U.S.C §120, this application relies on the earlier filing date of application serial number \_\_\_, filed on \_\_\_.

The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application.


This statement is being filed:

☐ with the application.

☐ within three months of the filing date of the application.

☒ before the receipt of a first Office Action on the merits.

☐ after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.

☐ I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated \_\_\_, which is not more than three months prior to filing of this statement.

☐ after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.

☐ Late submission fee \$ \_\_\_ under 37 CFR 1.17(p) is enclosed.

☐ after a final Office Action or a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated \_\_\_, which is not more than three months prior to filing this statement. Applicant hereby petitions under CFR 1.97(d) for this statement to be considered.


☐ Submission fee \$ \_\_\_ under 37 CFR 1.17(p) is enclosed.

☐ Please apply any additional charges or credits to Deposit Account No. \_\_\_.

SIGNATURE OF Applicant, Attorney, or Agent

Name	Adenike A. Adewuya	Registration No.	42,254
Signature	<i>Adenike Adewuya</i>	Telephone	281-477-3450
Date	7/9/04	Facsimile	281-477-3455
<input checked="" type="checkbox"/> *Total of <u>1</u> form PTO-1449 are submitted.			

<sup>1</sup> This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the enclosed documents constitute "prior art." If it should be determined that any of the submitted documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.



United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US	
Form PTO-1449 (Amended)		<b>Information Disclosure Citation</b>	
Application No.		10/698,894	Attorney Docket
Filed (yyyy-mm-dd)		2003-10-31	Customer No.
Applicant		Liang C. Dong	Confirmation No.
Examiner			Art Unit
Title		Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs	

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date yyyy-mm-dd	Applicant/Patentee

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date yyyy-mm-dd	Applicant/Patentee	T
	B1	WO 99/01113	1999-01-14	Pfizer Products Inc.	
	B2	WO 00/13674	2000-03-16	Alza Corporation	
	B3	WO 02/07712	2002-01-31	Pharmacia & Upjohn Company	
	B4	WO 03/053400	2003-07-03	Alza Corporation	

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	

EXAMINER: \_\_\_\_\_ DATE CONSIDERED: \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.